Cogent Biosciences, Inc.
COGT
주식 순위
#3382
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
주가
$29.64
마지막 동기화: 2026-10-16
시가총액
$5.14B
변동 (1일)
0.44%
변동 (1년)
80.83%
국가
US
거래 Cogent Biosciences, Inc. (COGT)
카테고리
Healthcare
Cogent Biosciences, Inc. (COGT)의 EPS
June 2026 기준 EPS TTM: $-2.31
Cogent Biosciences, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-2.31입니다. 2023년 말에는 회사의 EPS가 $-2.42였으며, 이는 2022년의 EPS $-2.26와 증가입니다.
Cogent Biosciences, Inc.의 EPS 기록 (2015 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-2.31 | -6.10% |
| 2024 | $-2.46 | 1.65% |
| 2023 | $-2.42 | 7.08% |
| 2022 | $-2.26 | 22.16% |
| 2021 | $-1.85 | -69.17% |
| 2020 | $-6.00 | 51.13% |
| 2019 | $-3.97 | -28.47% |
| 2018 | $-5.55 | 60.87% |
| 2017 | $-3.45 | 11.29% |
| 2016 | $-3.10 | 174.34% |
| 2015 | $-1.13 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -849.78% |
US
|
|
| $-7.98 | 245.45% |
US
|
|
| $-5.29 | 129.00% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,300.87% |
NL
|
